Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide versus acarbose versus standard treatment in overweight adults with type 2 diabetes on oral agents and high-dose insulin
ISRCTN47355247Phase 4Terminated
- Sponsor
- Glangwili General Hospital
- Start
- Aug 2010
- Modality
- Peptides, Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of liraglutide and acarbose in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Glangwili General Hospital. Primary endpoint: Improvement in glycaemic control. Started Aug 2010; status: terminated.
02
Drugs
liraglutideacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN47355247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47355247.